Registry Study for Optimal Management of Liver Failure in the Chinese Population
RESOLVE-C
1 other identifier
observational
500
1 country
14
Brief Summary
Liver failure is the most severe form of liver damage caused by viral, alcoholic, drug-related and ischemia-reperfusion factors, often combined with extrahepatic organ damage, resulting in a high mortality rate. This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics, epidemiology of bacterial and fungal infections, the impact of sarcopenia on clinical prognosis, and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure. The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection, end-stage liver disease combined with organ failure, and early warning of critically ill patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2023
Longer than P75 for all trials
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 6, 2023
CompletedFirst Submitted
Initial submission to the registry
February 8, 2023
CompletedFirst Posted
Study publicly available on registry
February 23, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2028
ExpectedFebruary 23, 2023
January 1, 2023
2 years
February 8, 2023
February 22, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Overall survival
28-day survival rates without liver transplantation
28-day
Overall survival
90-day survival rates without liver transplantation
90-day
Secondary Outcomes (1)
Disease progression
48 weeks after discharge
Study Arms (3)
ALF
acute liver failure
SALF
subacute liver failure
ACLF
acute-on-chronic liver failure
Interventions
Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks
The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks
On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
Eligibility Criteria
All patients receive guideline-based systemic therapy. The follow-up assessments will be performed at week 1, 2, 3, 4, 12, 24 and 48 or any time if there is a change in condition. All the patients receive routine biochemical tests and imaging examinations.
You may qualify if:
- Patients with a diagnosis consistent with liver failure and pre-liver failure:
- Extreme weakness with significant gastrointestinal symptoms such as anorexia, vomiting and abdominal distention;
- Elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) with progressive jaundice (TBil≥85.5 μmol/L);
- Bleeding tendency with PTA ≤ 60% or INR ≥ 1.5.
You may not qualify if:
- An event or complication that, in the judgment of the investigator, significantly affects the assessment of clinical status.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (14)
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
Ankang Central Hospital
Ankang, China
Xiangya Hospital of Central South University
Changsha, China
Hanzhong 3201 Hospital
Hanzhong, China
Qilu Hospital of Shandong University
Jinan, China
First Hospital of Lanzhou University
Lanzhou, China
Weinan Central Hospital
Weinan, China
Air Force Medical University Tangdu Hospital
Xi'an, China
Shaanxi provincial people's hospital
Xi'an, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Xi 'an International Medical Center Hospital
Xi'an, China
Xianyang Central Hospital
Xianyang, China
The Affiliated Hospital of Yan'an University
Yanan, China
General Hospital of Ningxia Medical University
Yinchuan, China
Related Publications (1)
Liu Y, Zhang Q, Li J, Wu X, Zang Q, Wang Q, Huang P, Wang Y, Zhang S, Liu S, Zhu C, Zhao Y, Yan T, He Y. mNGS improves the efficiency of infection diagnosis and treatment in acute-on-chronic liver failure. BMC Gastroenterol. 2026 Jan 20. doi: 10.1186/s12876-025-04601-8. Online ahead of print.
PMID: 41559596DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Yingli He, Pro.
First Affiliated Hospital Xi'an Jiaotong University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 2 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 8, 2023
First Posted
February 23, 2023
Study Start
January 6, 2023
Primary Completion
December 30, 2024
Study Completion (Estimated)
December 30, 2028
Last Updated
February 23, 2023
Record last verified: 2023-01